|
|
Remune
is an injected vaccine intended to help HIV-infected individuals
mount immune responses against the virus. Remune appears
to have improved immune function in HIV+ volunteers in
some earlier studies. |
|
Objective
|
To
determine whether adding Remune to standard HIV triple-drug
therapy causes the HIV therapy to work for a longer time. |
|
|
A
Phase III, double-blind, placebo-controlled, 56 week study.
All participants will receive HIV triple-drug therapy
throughout the study at no cost to them. This study compares
standard HIV triple-drug therapy (AZT, 3TC, Viracept)
with injections of Remune to the same triple-drug therapy
with injections of a placebo. Injections of Remune or
placebo will occur once every 12 weeks. |
|
Inclusion
Criteria
|
- Have
never taken antiretrovirals before.
- HIV+
man or woman, at least 18 years old.
- Viral
load greater than or equal to 10,000 copies.
- T-cell
count greater than or equal to 250.
- Women
who are not pregnant and are willing to use contraceptives
for the duration of the study.
|
|
Status
__
|
Enrolling
--
|
For
more information about participating in this study
in the Los Angeles area, please call 310/358.2429
or e-mail Corie Castro at ccastro@aidsresearch.org
|
|
We
encourage participation by women and people of color.
This
ad was reviewed and approved by the AIDS Research Alliance
Institutional Review Board on August 15, 2000.
|
